Skip to main content Skip to search Skip to main navigation
 Get a free Melatonin Spray with purchases over €100  Get a free Melatonin Spray with purchases over €100 X
Menu
Premium Nahrungsergänzungsmittel | artgerecht

D56.3 – Thalassaemia Minor: Causes & Diagnosis

D56.3 is the ICD-10 code for thalassaemia minor, a hereditary blood disorder affecting haemoglobin production. Most carriers experience mild or no symptoms.

Regular tips about health Regular tips about health
Lexicon Navigation

Things worth knowing about "D56.3"

D56.3 is the ICD-10 code for thalassaemia minor, a hereditary blood disorder affecting haemoglobin production. Most carriers experience mild or no symptoms.

What is D56.3 – Thalassaemia Minor?

D56.3 is the ICD-10 diagnosis code for thalassaemia minor, also known as the thalassaemia trait or carrier state. It is a hereditary disorder affecting the synthesis of haemoglobin – the protein in red blood cells responsible for carrying oxygen. In thalassaemia minor, only one defective gene copy is present, meaning the condition is usually mild or entirely asymptomatic.

Causes

Thalassaemias are caused by genetic mutations that reduce or impair the production of alpha- or beta-globin chains, which are essential components of haemoglobin. In thalassaemia minor (D56.3), the affected person has inherited only one defective gene copy (heterozygous form). The second gene copy functions normally, allowing sufficient haemoglobin production to continue.

  • Beta-thalassaemia minor: Mutation in the HBB gene on chromosome 11
  • Alpha-thalassaemia minor: Deletion or mutation affecting one to two alpha-globin genes on chromosome 16
  • Autosomal recessive inheritance: Both parents can be carriers without being severely affected themselves

Symptoms

Thalassaemia minor is frequently asymptomatic and may go unnoticed for years. When symptoms do occur, they are typically mild:

  • Mild anaemia with slightly reduced haemoglobin levels
  • Small red blood cells (microcytosis) and pale red blood cells (hypochromia)
  • Occasional fatigue or reduced stamina during physical activity
  • Mild enlargement of the spleen (splenomegaly) in rare cases

During pregnancy, thalassaemia minor may increase iron requirements and worsen any existing anaemia, requiring closer monitoring.

Diagnosis

Thalassaemia minor is typically identified through a full blood count and confirmatory tests:

  • Full blood count (FBC): Low MCV (mean corpuscular volume) and low MCH (mean corpuscular haemoglobin) values are characteristic findings
  • Haemoglobin electrophoresis or HPLC: Elevated HbA2 levels confirm beta-thalassaemia minor
  • Molecular genetic testing: Identifies the specific mutation; especially important for family planning
  • Ferritin and serum iron: To rule out concurrent iron deficiency anaemia, which can present similarly

Treatment

Since thalassaemia minor is usually asymptomatic, no specific treatment is generally required. However, the following measures are relevant:

  • Regular blood count monitoring to track any changes
  • Avoid unnecessary iron supplementation: Iron therapy is only appropriate if iron deficiency is confirmed – otherwise, iron overload can occur
  • Genetic counselling: Essential for couples planning a family, as two carriers have a 25% chance with each pregnancy of having a child with severe thalassaemia major (D56.1)
  • During pregnancy: Close monitoring, folic acid supplementation, and collaboration between obstetric and haematological care teams

Genetic Counselling and Family Planning

When both partners are carriers of thalassaemia minor, there is a 25% probability with each pregnancy that the child will inherit thalassaemia major, a severe and potentially life-threatening condition requiring regular blood transfusions. Prenatal diagnosis and genetic counselling are strongly recommended. In countries with a high carrier frequency – including the Mediterranean region, the Middle East, and Southeast Asia – national screening programmes are in place.

References

  1. World Health Organization (WHO): Management of Haemoglobin Disorders. Report of a Joint WHO-TIF Meeting, Nicosia, 2007.
  2. Galanello R, Origa R: Beta-thalassemia. Orphanet Journal of Rare Diseases, 2010; 5:11. DOI: 10.1186/1750-1172-5-11.
  3. Weatherall DJ: The inherited diseases of haemoglobin are an emerging global health burden. Blood, 2010; 115(22): 4331–4336. DOI: 10.1182/blood-2010-01-251348.

Most purchased products

Discount
natural iron supplement premium plantderived mineralcomplex?ts=1751927698

Average rating of 4.94 out of 5 stars

Natural Iron

For your iron balance

Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
UV glass
Lab tested
Non-GMO
No additives
Cologne List
Gluten free
Lactose free
100% vegetarian fermentation
30 Capsules
30 Capsules
Sale price: €29.90 Regular price: €35.90
Product Quantity: Enter the desired amount or use the buttons to increase or decrease the quantity.
lactoferrin kapseln 60 premium eisenbindung immunschutz laktosefrei milch?ts=1751997240

Average rating of 4.85 out of 5 stars

Lactoferrin 60 Capsules

For your universal protection

As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
UV glass
Lab tested
Non-GMO
No additives
Cologne List
Lactose free
Pure CLN
60 Capsules
60 Capsules
Regular price: €59.90
Product Quantity: Enter the desired amount or use the buttons to increase or decrease the quantity.
floral lactoferrin cln mundflora lutschtabletten?ts=1779887262

Average rating of 4.96 out of 5 stars

Floral

For Healthy Oral Flora & Dental Care

Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
Sugar free
Lab tested
Non-GMO
Cologne List
Lactose free
Tooth friendly
GMP Quality
Clinical proofed
Pure CLN
30 lozenges
Regular price: €22.90
Product Quantity: Enter the desired amount or use the buttons to increase or decrease the quantity.

The latest entries

3 Posts in this encyclopedia category

TBE Treatment

TBE treatment focuses on relieving symptoms, as no specific antiviral therapy exists. Vaccination and tick prevention are the most effective protective measures.

Nephroprotection profile

The nephroprotection profile describes the overall kidney-protective properties of a therapy or active substance and is a key concept in nephrology and chronic kidney disease management.

M47.2

M47.2 is the ICD-10 code for spondylosis with radiculopathy – a degenerative spinal condition in which bony or disc changes compress nerve roots, causing pain, tingling, or weakness.

Related search terms: D56.3